Thomas Suozzi
← all tradesD · U.S. House · NY03
530 disclosed stock trades on file across 156 tickers · traded 2017-01-05 to 2026-02-18 · latest disclosure 2026-02-19. Reported under the STOCK Act. Amounts are the disclosed ranges, not exact values; “lag” is days from trade to disclosure. As disclosed — not investment advice. methodology → sources →
Thomas SuozziDHouse · NY03· estimated positions — what they still seem to hold methodology → sources →
← all tradesAlso filed as “Hon. Thomas R. Suozzi” — merged as one member (by chamber, state/district and surname) because the feed has no member ID and spells one person several ways. Each row keeps its filed name.
Who's trading this portfolioshare of disclosed $ volume · range midpoints
Member 100%Spouse 0%
Disclosed trades
most recent first · the 10 most recent disclosures
| Ticker | Type | Amount | Trade date | Disclosed | Lag |
|---|---|---|---|---|---|
| URI | SELL | $15,001–$50,000 | 2026-02-18 | 2026-02-19 | 1d |
| PLTR | SELL | $15,001–$50,000 | 2026-02-18 | 2026-02-19 | 1d |
| AAPL | SELL | $15,001–$50,000 | 2026-02-18 | 2026-02-19 | 1d |
| AMD | SELL | $1,001–$15,000 | 2026-02-18 | 2026-02-19 | 1d |
| WY | SELL | $1,001–$15,000 | 2025-10-14 | 2025-10-16 | 2d |
| WMT | SELL | $15,001–$50,000 | 2025-10-14 | 2025-10-16 | 2d |
| NEE | SELL | $1,001–$15,000 | 2025-10-14 | 2025-10-16 | 2d |
| INPAP | SELL | $1,001–$15,000 | 2025-10-14 | 2025-10-16 | 2d |
| GIC | SELL | $15,001–$50,000 | 2025-03-31 | 2025-04-01 | 1d |
| NVDA | SELL | $1,001–$15,000 | 2024-10-02 | 2024-11-07 | 36d |
Showing the 10 most recent of 530 disclosed trades — sign in free to see more. Create a free account →See it live on AAPL →
Filings on paper
The House publishes these reports as scanned images. Each link opens the filing on the Clerk's own site.
2022
Filed 2022-12-01view at the House Clerk →
Filed 2022-10-14view at the House Clerk →
Filed 2022-09-15view at the House Clerk →
Related· who else trades these names
Related· executive-branch officials who also traded these names
A model's estimate — for research. See the Disclaimer.